|
|
Volumn 33, Issue 8, 2009, Pages 1022-1023
|
|
Laromustine: The return of alkylators to non-myeloablative therapy of AML
|
|
Author keywords
Alkylating agents; AML; Anthracyclines; ATG; Cloretazine; Cytarabine; Elderly; Laromustine; VNP40101M
|
|
Indexed keywords
1,2 BIS(METHYLSULFONYL) 1 (2 CHLOROETHYL) HYDRAZINE;
6 O ALKYLGUANINE DNA ALKYLTRANSFERASE;
ALKYLATING AGENT;
ANTHRACYCLINE;
CYTARABINE;
DAUNORUBICIN;
GLUTATHIONE;
GLUTATHIONE TRANSFERASE;
HISTONE H2AX;
HYDRAZINE DERIVATIVE;
LAROMUSTINE;
METHYL ISOCYANATE;
UNCLASSIFIED DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
AGED HOSPITAL PATIENT;
ALKYLATION;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
BONE MARROW SUPPRESSION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER EPIDEMIOLOGY;
CANCER MORTALITY;
CANCER PATIENT;
CANCER REGRESSION;
CANCER RELAPSE;
CELL PROLIFERATION;
CELL VIABILITY;
CLINICAL TRIAL;
CONTINUOUS INFUSION;
DNA CROSS LINKING;
DNA STRAND BREAKAGE;
DNA SYNTHESIS INHIBITION;
DRUG ACTIVITY;
DRUG CYTOTOXICITY;
DRUG DNA BINDING;
DRUG FATALITY;
DRUG HALF LIFE;
DRUG INHIBITION;
DRUG MEGADOSE;
DRUG METABOLISM;
DRUG POTENTIATION;
EDITORIAL;
ENZYME ACTIVITY;
ENZYME INHIBITION;
GASTROINTESTINAL TOXICITY;
HUMAN;
IN VITRO STUDY;
MYELODYSPLASTIC SYNDROME;
NONMYELOABLATIVE CONDITIONING;
PNEUMONIA;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN SYNTHESIS INHIBITION;
RECOMMENDED DRUG DOSE;
RNA SYNTHESIS;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
APOPTOSIS;
CELL LINE, TUMOR;
CELL PROLIFERATION;
CELL SURVIVAL;
CYTARABINE;
DAUNORUBICIN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG SCREENING ASSAYS, ANTITUMOR;
HUMANS;
HYDRAZINES;
LEUKEMIA, MYELOID, ACUTE;
SULFONAMIDES;
|
|
EID: 67349127117
PISSN: 01452126
EISSN: None
Source Type: Journal
DOI: 10.1016/j.leukres.2009.02.002 Document Type: Editorial |
|
Times cited : (5)
|
|
References (8)
|
